Integration of behavioral health and wellbeing solutions with navigation and engagement technology creates the most comprehensive solution in the market under the Dario brand
NEW YORK, Oct. 17, 2024 /PRNewswire/ — DarioHealth Corp. (Nasdaq: DRIO) (“Dario” or the “Company”), a global leader in digital health, today announces the full integration of Twill’s advanced behavioral health and navigation capabilities into the Dario platform. The integration completes Dario’s effort to create one of the most comprehensive and effective end-to-end digital health solutions in the market. By unifying data across mental and physical health, Dario offers a more personalized and effective approach to care.
With the prior acquisition of Twill, Dario has expanded both vertically and horizontally, reinforcing its position as the premier platform for multi-chronic condition management. The vertical expansion integrates behavioral health as a stand-alone condition as well as a core element across all existing chronic condition management programs. This means that, whether managing a cardiometabolic or musculoskeletal condition, Dario now addresses both the mental and physical aspects of member journeys, offering a more holistic solution that improves overall outcomes. This achievement unlocks the foundational benefit of incorporating behavioral health support into chronic condition management and addresses a fundamental need that Dario has recognized in the market for a more complete solution that spans across co-existing conditions.
Horizontal expansion broadens the platform’s reach by incorporating Twill’s powerful navigation capabilities that guide users throughout their health journey, helping them manage multiple, interconnected conditions—from prevention to continuous care—through a single, integrated platform. This enables a seamless experience where users receive personalized support at every step, enhancing engagement and outcomes across the board. The newly integrated Twill engagement capabilities can be deployed across various market channels with a strong approach to finding and activating members. The top of funnel solution aligns with each client’s specific needs.
Emerging as a unified, single-brand solution:
The fully integrated suite of solutions and associated technologies that aim to support a full spectrum of physical and mental health needs will now be captured under the Dario brand. Support for each of the six covered conditions is incorporated in the platform which is structured around four core offerings:
“Our vision from the beginning of the acquisition of Twill has been clear: to build the most comprehensive, integrated digital health platform in the market,” said Erez Raphael, CEO of Dario. “We’ve strengthened our platform by integrating behavioral health as a core capability across every chronic condition we manage. We believe that the ability to help members navigate available care and support by deploying Dario’s AI-driven journey engine across unified mental and physical health data and providing a more personalized and outcomes-focused approach to engagement represents a game-changing shift for both members and clients.”
“The full Dario suite improves access to a powerful behavior change engine designed to optimize clinical outcomes and improve overall health. Our unique ability to engage people at any stage in their health journey and aim to navigate them to the right level of digital care in a single, unified experience, has the potential to solve two of the biggest pain points for payers, employers and pharma companies: point solution fatigue and poor engagement. We are thrilled to move to the next generation of truly consumer-centered digital health that we believe will make a significant difference for member health and generate better ROI for our partners,” said Keren Zimmerman, Chief Product Officer of Dario.
About DarioHealth Corp.
DarioHealth Corp. (Nasdaq: DRIO) is a global digital health company dedicated to transforming the way people manage chronic conditions through its user-centric, multi-condition digital therapeutics platform. Dario’s comprehensive platform leverages data analytics, AI, and personalized coaching to deliver continuous care for diabetes, hypertension, musculoskeletal health, weight management, and behavioral health. By empowering individuals to take control of their health through behavior change, Dario is revolutionizing the digital health landscape.
For more information, visit www.dariohealth.com.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses the benefits of the integration of Twill’s capabilities into the Dario platform; that the integrated Twill capabilities can be deployed across various collaboration channels for engaging members; that the integrated suite of solutions will support a full spectrum of physical and mental health needs and will now be captured under the Dario brand; that Dario’s platform will be the most comprehensive, integrated digital health platform in the market; that the Twill integration represents a game-changing shift for both members and clients; the potential of Dario’s platform to solve two of the biggest pain points for payers, employers and pharma companies; and that the move to the next generation of consumer-centered digital health will make a significant difference for member health and generate better return on investment for Dario’s partners. Without limiting the generality of the foregoing, words such as “plan,” “project,” “potential,” “seek,” “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate” or “continue” are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company’s results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company’s actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company’s filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company’s commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
DarioHealth Corporate Contact
Mary Mooney
VP Marketing
mary@dariohealth.com
+1-312-593-4280
DarioHealth Investor Relations Contact
Kat Parrella
Investor Relations Manager
kat@dariohealth.com
+315-378-6922
Media Contact
Scott Stachowiak
Scott.Stachowiak@russopartnersllc.com
+1-646-942-5630
Logo – https://healthtechnologynet.com/wp-content/uploads/2024/10/DarioHealth_Logo-1.jpg
SOURCE DarioHealth Corp.
NEWTOWN, Pa., Dec. 22, 2024 /PRNewswire/ -- The law firm of Edelson Lechtzin LLP is…
Miami, Florida--(Newsfile Corp. - December 21, 2024) - Amid the vibrant backdrop of Art Basel…
Daily Fit Notes, founded by Justin Brey in New York, launches a text-based subscription fitness…
MT. STERLING, Ohio, Dec. 20, 2024 /PRNewswire/ -- WillowWood, a global leader in prosthetic solutions,…
TORONTO, ON / ACCESSWIRE / December 20, 2024 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma"…
Toronto, Ontario--(Newsfile Corp. - December 20, 2024) - Glow Lifetech Corp. (CSE: GLOW) (OTC Pink:…